Abstract
Current antipsychotic drugs lack material efficacy against the negative symptoms and cognitive deficits of schizophrenia. There is considerable uncertainty regarding the optimal pharmacotherapeutic strategy for treating these and other aspects of psychotic illness. The present review summarises clinical, mutant, and psychopharmacological data related to catechol-O-methyltransferase (COMT), an enzyme involved in the catabolism of catecholamine neurotransmitters, with a view to establishing the antipsychotic potential of compounds targeting the action of this enzyme. The review examines clinical and preclinical genetic data linking COMT gene variation with risk for schizophrenia or specific symptoms or disease endophenotypes. We then summarise data concerning the behavioural effects of COMT inhibitors. These genetic and pharmacological data relating to COMT as a therapeutic target have implications for the development of individualised treatments for treatment-resistant symptoms of schizophrenia, including cognitive dysfunction and, potentially, negative symptoms.
Keywords: Catechol-O-methyltransferase, schizophrenia, antipsychotics, cognition, negative symptoms, Psychotic illness, 22q11-deletion syndrome, Valine, Mrthionine, Cannabis
CNS & Neurological Disorders - Drug Targets
Title:Catechol-O-Methyl Transferase as a Drug Target for Schizophrenia
Volume: 11 Issue: 3
Author(s): Colm M.P. O’Tuathaigh, Lieve Desbonnet, Peter Lee and John L. Waddington
Affiliation:
Keywords: Catechol-O-methyltransferase, schizophrenia, antipsychotics, cognition, negative symptoms, Psychotic illness, 22q11-deletion syndrome, Valine, Mrthionine, Cannabis
Abstract: Current antipsychotic drugs lack material efficacy against the negative symptoms and cognitive deficits of schizophrenia. There is considerable uncertainty regarding the optimal pharmacotherapeutic strategy for treating these and other aspects of psychotic illness. The present review summarises clinical, mutant, and psychopharmacological data related to catechol-O-methyltransferase (COMT), an enzyme involved in the catabolism of catecholamine neurotransmitters, with a view to establishing the antipsychotic potential of compounds targeting the action of this enzyme. The review examines clinical and preclinical genetic data linking COMT gene variation with risk for schizophrenia or specific symptoms or disease endophenotypes. We then summarise data concerning the behavioural effects of COMT inhibitors. These genetic and pharmacological data relating to COMT as a therapeutic target have implications for the development of individualised treatments for treatment-resistant symptoms of schizophrenia, including cognitive dysfunction and, potentially, negative symptoms.
Export Options
About this article
Cite this article as:
M.P. O’Tuathaigh Colm, Desbonnet Lieve, Lee Peter and L. Waddington John, Catechol-O-Methyl Transferase as a Drug Target for Schizophrenia, CNS & Neurological Disorders - Drug Targets 2012; 11 (3) . https://dx.doi.org/10.2174/187152712800672418
DOI https://dx.doi.org/10.2174/187152712800672418 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacology and Therapeutic Applications of A1 Adenosine Receptor Ligands
Current Topics in Medicinal Chemistry Emerging Anticoagulants
Current Medicinal Chemistry Nitric Oxide and its Antithrombotic Action in the Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Beta Blockers and Chronic Obstructive Pulmonary Disease (COPD): Sum of Evidence
Current Hypertension Reviews Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Cardiac and Muscular Involvement in Idiopathic Inflammatory Myopathies: Noninvasive Diagnostic Assessment and the Role of Cardiovascular and Skeletal Magnetic Resonance Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Effect of GLP-1 Based Therapies on Diabetic Dyslipidemia
Current Diabetes Reviews Energy Metabolism in the Normal and in the Diabetic Heart
Current Pharmaceutical Design Brachial-Ankle Pulse Wave Velocity in the Measurement of Arterial Stiffness: Recent Evidence and Clinical Applications
Current Hypertension Reviews Laboratory Techniques for Human Viral Encephalitis Diagnosis
Infectious Disorders - Drug Targets Cardiac and Renal Nitric Oxide in the Adaptation to Hypovolemic Shock
Current Enzyme Inhibition Instructions from the Vascular System - Directing Neural Stem Cell Fate in Health and Disease
Current Medicinal Chemistry Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
Current Neuropharmacology Torsades de Pointes in Patients with Polymyalgia Rheumatica
Current Pharmaceutical Design Beta-Blockers in Pediatric Hypertrophic Cardiomyopathies
Reviews on Recent Clinical Trials Recent Insights into the Role of Prostanoids in Atherosclerotic Vascular Disease
Current Vascular Pharmacology Obesity and Arterial Compliance Alterations
Current Vascular Pharmacology New Strategies for Managing Anemia of Chronic Kidney Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry